Record quarter and strong pipeline
Oslo, Norway (13 November 2019) NattoPharma increased revenues by 31% in the third quarter and 25% for the first nine months of 2019. Adjusted EBITDA in the quarter came in at NOK 3,2 million. (mnok) Q3’19 Q3’18 YTD’19 YTD’18Product Revenue 30,9 23,6 88,6 70,8Gross Margin 43,0% 45,5% 42,0% 42,9%EBITDA (adj.) 3,2 1,1 6,0 3,6 CEO, Kjetil Ramsøy: “We are very pleased with this quarter. It shows the scalability of our business model as we can sell more product without adding additional overhead cost. The underlying revenue growth